c-erbB-2、ER、PR在乳腺癌中的表达及其临床意义

Expressions of c-erbB-2,ER and PR in Breast Cancer and Their Clinical Significances

目的探讨c-erbB-2、雌激素受体(ER)、孕激素受体(PR)在乳腺癌中的表达及其临床意义。方法采用免疫组化方法检测54例乳腺癌患者中c-erbB-2、ER、PR的表达,并分析其与临床的关系。结果54例乳腺癌中,ER、PR、c-erbB-2的阳性表达率分别为48.2%(26/54)、53.7%(29/54)、72.2%(39/54)。ER、PR的阳性表达率与患者年龄、有无淋巴结转移及组织学类型的差异无统计学意义(P>0.05);c-erbB-2阳性表达率与有无淋巴结转移的差异有统计学意义(P<0.05),与患者年龄、肿瘤体积及组织学类型的差异无统计学意义(P>0.05);ER、PR与c-erbB-2表达一致率为46.3%(25/54),表达不一致率为27.8%(15/54),ER、PR表达与c-erbB-2表达无显著相关性(P>0.05)。结论c-erbB-2的阳性表达是乳腺癌患者预后差的指标,联合检测ER、PR更有助于乳腺癌患者临床疗效和预后的判断。

Objective To investigate the expressions of c-erbB-2, estrongen receptor（ER）, proges- terone（PR） in breast cancer tissue and their clinical significance. Methods The expression of c-erbB- 2, ER, PR in 54 cases of breast cancer tissue were assessed by immunohistochemistry, and the correla- tion between that and its clinical significance was statistically analyzed. Results Positive expression rate of c-erbB-2, ER, PR in 54 cases of breast cancer tissue was 48.2% （26/54）, 53.7% （29/54）, 72.2% （39/54）, the expression of ER,PR didn＇t cor relate to age, lymph node status and the structural type of breast cancers（P 〉0.05）. Expression of c-erbB-2 correlated with lymph node status（P 〈0.05）, didn＇t correlate to age, lymph node status and the structural type of breast cancer（P 〉 0.05）. The consistent rate of c-erbB-2, ER, PR in 54 casees of breast cancer tissue was 46.3 % （25/ 54）, different rate was 27.8 % （15/54）, the expression of ER、PR was not associated with c-erbB-2 （P 〉0.05）. Conclusion c-erbB-2 positive expression is a poor prognosis factor for breast cancer pa- tients. Combined detection of ER and PR may be helpful to clinical treatment and prognostic judgement on breast cancer patients.